reports
Evolus Inc: 1 director
A director at Evolus Inc sold 127,905 shares at 10.032USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
EME EMCOR GROUP
CMCSA COMCAST CORPORATION CLASS A
LII LENNOX INTERNATIONAL INC.
WDC WESTERN DIGITAL CORPORATION
VNO VORNADO REALTY TRUST
TXT TEXTRON INC.
PNR PENTAIR PLC
ORRF ORRSTOWN FINANCIAL SERVICES INC.
ON ON SEMICONDUCTOR CORPORATION
NYCB NEW YORK COMMUNITY BANCORP INC.
FORM FORMFACTOR INC.
CRS CARPENTER TECHNOLOGY CORPORATION
AR ANTERO RESOURCES CORPORATION
AMSC AMERICAN SUPERCONDUCTOR CORP.
AEIS ADVANCED ENERGY INDUSTRIES INC.
QUAD QUAD/GRAPHICS INC. CLASS A
JOE ST. JOE COMPANY
CCL CARNIVAL CORPORATION
HLX HELIX ENERGY SOLUTIONS GROUP INC.
HP HELMERICH & PAYNE INC.
VSTO VISTA OUTDOOR INC
BF.A BROWN-FORMAN CORP. CL A
ITGR INTEGER HOLDINGS CORPORATION
USAP UNIVERSAL STAINLESS & ALLOY PRODUCTS INC.
URGN UROGEN PHARMA
EOLS EVOLUS INC
CMPR CIMPRESS PLC
CARR CARRIER GLOBAL CORP.
TARS TARSUS PHARMACEUTICALS
OS OFFICINA STELLARE
TCBX THIRD COAST BANCSHARES INC
FAF FIRE & FLOWERS HLDGS CORP
N INCO LTD.
- Jonathan Moreland
TCX TUCOWS INC.
OPK OPKO HEALTH INC.
NVDA NVIDIA CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NDLS NOODLES & COMPANY
IMMR IMMERSION CORP.
HBI HANESBRANDS INC.
GHL GREENHILL & CO. INC.
DISH DISH NETWORK CORPORATION CLASS A
CRK COMSTOCK RESOURCES INC.
COMM COMMSCOPE HOLDING CO. INC.
CINF CINCINNATI FINANCIAL CORPORATION
AAT AMERICAN ASSETS TRUST INC.
DGICA DONEGAL GROUP INC. CL A
UFCS UNITED FIRE GROUP INC.
MEDP MEDPACE HOLDINGS INC.
PBI PITNEY BOWES INC.
SPOK SPOK HOLDINGS
JELD JELD-WEN HOLDING INC.
HOG HARLEY-DAVIDSON INC.
EOLS EVOLUS INC
TCDA TRICIDA
GIM TEMPLETON GLOBAL INCOME FUND
LQDA LIQUIDIA CORPORATION
ELAN ELANCO ANIMAL HEALTH INC.
PVH PHILLIPS-VAN HEUSEN CORPORATION
HCAT HEALTH CATALYST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
GLT GLATFELTER CORPORATION
PRMW PRIMO WATER CORPORATION
RILY B. RILEY FINANCIAL
ASAN ASANA
SLQT SELECTQUOTE
DASH INC.
LSEA DOORDASH
PACK LANDSEA HOMES CORP (A)
TERN RANPAK HOLDINGS (A)
PHX TERNS PHARMACEUTICALS
PFX PANHANDLE OIL AND GAS INC
LAZR PHENIXFIN CORP
COIN LUMINAR TECHNOLOGIES INC (A)
SQSP COINBASE GLOBAL
MKTW INC.
WISH SQUARESPACE
NYC INC.
RKT MARKETWISE
CASI INC.
MRVL CONTEXTLOGIC INC.
MTTR NEW YORK CITY REIT INC
ROCKET SHARING COMPANY SPA
CASI PHARMACEUTICALS INC.
MARVEL BIOSCIENCES CORP
MATTERPORT
INC./DE
- Jonathan Moreland
HBI HANESBRANDS INC.
CRK COMSTOCK RESOURCES INC.
AAT AMERICAN ASSETS TRUST INC.
UFCS UNITED FIRE GROUP INC.
PBI PITNEY BOWES INC.
EOLS EVOLUS INC
ELAN ELANCO ANIMAL HEALTH INC.
ETNB 89BIO
ASAN ASANA
LSEA LANDSEA HOMES CORP (A)
PACK RANPAK HOLDINGS (A)
PHX PANHANDLE OIL AND GAS INC
PFX PHENIXFIN CORP
LAZR LUMINAR TECHNOLOGIES INC (A)
COIN COINBASE GLOBAL
SQSP INC.
MKTW SQUARESPACE
WISH INC.
TSE MARKETWISE
RKT INC.
OPFI CONTEXTLOGIC INC.
TRINSEO PLC
ROCKET SHARING COMPANY SPA
OPPFI INC
- Jonathan Moreland
NVDA NVIDIA CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
HBI HANESBRANDS INC.
DISH DISH NETWORK CORPORATION CLASS A
CRK COMSTOCK RESOURCES INC.
MEDP MEDPACE HOLDINGS INC.
CLF CLIFFS NATURAL RESOURCES INC.
CSBB C S B BANCORP OHIO
EOLS EVOLUS INC
GIM TEMPLETON GLOBAL INCOME FUND
HCAT HEALTH CATALYST
NREF NEXPOINT REAL ESTATE FINANCE
GLT INC.
PRMW GLATFELTER CORPORATION
RILY PRIMO WATER CORPORATION
DASH B. RILEY FINANCIAL
TERN DOORDASH
CASI TERNS PHARMACEUTICALS
BLIN CASI PHARMACEUTICALS INC.
BRIDGELINE DIGITAL INC
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Signs of Disinflation? A bear market bounce is underway after the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM) found support at their respective downtrend channels, a possibility we discussed last week. Still, until the S&P 500, QQQ, and IWM can break above their various downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure. Signs of Disinflation? We are starting to see early signs that inflation is peaking, as commodity prices have pulled...
INCY INCYTE CORP
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SNYN SANOFI S.A. ADS
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
JNJ JOHNSON & JOHNSON
CPRX CATALYST PHARMACEUTICALS
CORT CORCEPT THERAPEUTICS INCORPORATED.
BMY BRISTOL-MYERS SQUIBB COMPANY
BIIB BIOGEN INC.
AERI AERIE PHARMACEUTICALS INC.
NVS.. NOVARTIS AG ADS
PFE PFIZER INC.
PRPH PROPHASE LABS INC
ABBV ABBVIE INC.
OPTN OPTINOSE
GS7A GLAXOSMITHKLINE PLC (ADR)
EOLS EVOLUS INC
AZN ASTRAZENECA PLC ADS
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AMBA AMBARELLA INC.
ADSK AUTODESK INC.
EOLS EVOLUS INC
LTHM LIVENT
TPTX TURNING POINT THERAPEUTICS
DELL DELL TECHNOLOGIES INC CLASS C
UONE URBAN ONE
TLS TELOS
OI O-I GLASS INC
BMEA BIOMEA FUSION INC
ENVX ENOVIX CORP
OLPX OLAPLEX HLDGS INC
CYXT CYXTERA TECHNOLOGIES INC
ARIS ARIS WATER SOLUTIONS INC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Evolus Announces Participation in November Investment Conferences
Evolus Announces Participation in November Investment Conferences NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November. Event:Stifel 2021 Virtual Healthcare Conference Date:Tuesday, November 16, 2021 Time:2:40 pm ET Event:Evercore ISI 4th Annual HealthCONx Virtual Conference Date:Tuesday, November 30, 2021 Time:7:30 am ET Audio webca...
Evolus Reports Third Quarter 2021 Results and Provides Business Update
Evolus Reports Third Quarter 2021 Results and Provides Business Update Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-EndInitiated Jeuveau® “Extra Strength” Phase II Clinical Program to Demonstrate Extended Duration NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. “We r...
Evolus Initiates Phase II Program with “Extra Strength” Dose for Exten...
Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration Program Designed to Offer Consumers an “Extra Strength” Dosing OptionEvolus is Uniquely Positioned to Capitalize on this Opportunity with the Company’s Aesthetics-Only Strategy and Jeuveau® Product PrecisionFirst Patient Enrollment Expected in Q1 2022; Expected Completion in 1H 2023 NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has init...
Evolus Announces Appointment of Jessica Novak as Senior Vice President...
Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry. “One of Evolus’ greatest assets is...
Evolus to Report Third Quarter 2021 Results and Provide Business Updat...
Evolus to Report Third Quarter 2021 Results and Provide Business Update NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same day. A question-and-answ...
Evolus Announces Participation in September Investment Conferences
Evolus Announces Participation in September Investment Conferences NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September. Event:H.C. Wainwright 23rd Annual Global Investment ConferenceDate:Monday, September 13, 2021Time:Available on-demand starting at 7:00am ET Event:Cantor 2021 Virtual Global Healthcare ConferenceDate:Tuesday, September 28, 20...
Evolus Reports Second Quarter 2021 Results and Provides Business Updat...
Evolus Reports Second Quarter 2021 Results and Provides Business Update Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million Exceeded Annualized Revenue Run Rate Goal of $100 Million Low Q2 Cash Burn Resulting in $131.7 Million Cash Position at Quarter-End On Track for European Launch in Early 2022, a $470 Million Market1 NEWPORT BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the second quarter e...
Evolus to Report Second Quarter 2021 Results and Provide Business Upda...
Evolus to Report Second Quarter 2021 Results and Provide Business Update NEWPORT BEACH, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2021 financial results and provide a business update on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answ...
Evolus Announces Appointment of David K. Erickson as Vice President, I...
Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program. “David brings more than 25 years of investor relations and healthcare industry exp...
Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Pa...
Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color NEWPORT BEACH, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a peer reviewed journal article was published in Dermatologic Surgery (April 2021) highlighting the efficacy and safety of prabotulinumtoxinA (Jeuveau®) for the treatment of moderate to severe glabellar lines, also known as frown lines between the eyes, in adult patients with Skin of Color...
Evolus Appoints Dan Stewart as Vice President and General Manager, Int...
Evolus Appoints Dan Stewart as Vice President and General Manager, International NEWPORT BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the company’s International business. “Dan has an extensive track record of success and a global reputation built from 20 years of experience in aesthetics,” said Crystal Muilenburg, Chief Marketing Officer. “We look forward to Dan l...
Evolus Reports First Quarter 2021 Results and Provides Business Update
Evolus Reports First Quarter 2021 Results and Provides Business Update Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact Full Resolution of International Trade Commission (ITC) Case Restructured Balance Sheet with March 31, 2021 Pro Forma Cash Position of $140 million1 On Track for a $100 million Annual Net Revenue Run Rate in Q2 2021 NEWPORT BEACH, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today provided a business update and rep...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.